2021

• Apr.

  Capital reduction(Capital: 30M yen, Capital reserve: 30M yen)

• Sep.

  3rd party allocation of shares

• Jul.

  Hiroyuki Mitani assumes the position of President and CEO.

2020

• Apr.

  3rd party allocation of shares

• Feb.

  Clinical trials started in the U.S.

2019

• Jul.

  FDA accepted IND

• Apr.

  3rd party allocation of shares

• Feb.

  3rd party allocation of shares

2018

• Oct.

  3rd party allocation of shares

2017

• Dec.

  3rd party allocation of shares

• Sep.

  3rd party allocation of shares

2013

• Apr.

  Capital reduction(Capital: 30M yen, Capital reserve: 31M yen)

2012

• Feb.

  3rd party allocation of shares

2011

• Apr.

  3rd party allocation of shares

2009

• May

  3rd party allocation of shares

• Jan.

  Non-clinical study started in the US

2008

• Sep.

  3rd party allocation of shares

• Aug.

  3rd party allocation of shares

2007

• Nov.

  Dev. of NCS-01 started in the US

• Oct.

  3rd party allocation of shares

• Sep.

  Completed acquisition of RENOMEDIX INSTITUTE INC.

• Mar.

  3rd party allocation of shares

2006

• Apr.

  3rd party allocation of shares

2004

• Dec.

  NC Medical Research, Inc. established
  Demonstration experiment of Medical Services Network System was initiated through METI Healthcare Services Support Project.